P140 tagged posts

LupuzorTM may become the 1st Specific and Non-Immunosuppressant Therapy for Lupus

P140

© Fanny Bonachera / IBMC / ICT / PDB. Modeling of the 3D structure of the P140 peptide. The P140 peptide corresponds to the 131-151 sequence of the nuclear ribonucleoprotein U1-70K, whose residue 140 is a phosphoserine (visible on the left).

This peptide is the subject of a CNRS patent (granted in 2009) and has already successfully completed phases I and II of its regulatory clinical trials. An international phase III pivotal trial will begin in a few days’ time in the US when the first patient starts the treatment, before the trial is extended to Europe. Phase III is the last stage in the testing of a candidate drug, before it can be given market approval. The launch of phase III was the subject of a meeting involving around a hundred physicians on December 11-12, in Paris.

Lupus is a ch...

Read More